To check the effectiveness of a true acupuncture treatment according to traditional Chinese medicine (TCM) in migraine without aura, researchers of the Department of Medico-Surgical Specialities of University of Padua in Italy compared true acunpuncture to a standard mock acupuncture protocol, an accurate mock acupuncture healing ritual, and untreated controls.

"Migraine prevalence is high and affects a relevant rate of adults in the productive phase of their life," says the study to be published in the journal Headache.

"Acupuncture has been increasingly advocated and used in Western countries for migraine treatment, but the evidence of its effectiveness still remains weak. A large variability of treatments is present in published studies and no acupoint selection according to TCM has been investigated so far; therefore, the low level of evidence of acupuncture effectiveness might partly depend on inappropriate treatment."

In the study, the patients were divided into the following 4 groups:
(1) group TA, treated with true acupuncture (according to TCM) plus Rizatriptan; (N=32)
(2) group RMA, treated with ritualized mock acupuncture plus Rizatriptan; (N=30)
(3) group SMA, treated with standard mock acupuncture plus Rizatriptan; (N=31)
(4) group R, without prophylactic treatment with relief therapy only (Rizatriptan); (N=39)

What is Rizatriptan? Rizatriptan is used to treat the symptoms of migraine headaches (severe, throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound and light). Rizatriptan is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and stopping the release of certain natural substances that cause pain, nausea, and other symptoms of migraine. Rizatriptan does not prevent migraine attacks.

The MIDAS Questionnaire was administered before treatment, at 3 and 6 months from the beginning of treatment, and the MIDAS Index (MI) was calculated. Rizatriptan intake was also checked in all groups of patients at all three time intervals. All patients had moderate to severe with no significant intergroup differences before treatment.